MyDosageBeta
Where to buyCheck a brandAbout us
Early access Nº 01

Pick your way. We'll email you the day it opens.

Free. Tell us where you are and which way you want — a prescriber, a compounding pharmacy, or checked research-use-only suppliers.

Get started
  • Early access
  • Where to buy
  • Check a brand
  • Scan my product
  • Guide me
The three ways
  • Approved medicines
  • Compounding pharmacies
  • Lab (RUO) suppliers
Understand
  • Goals
  • Conditions
  • Side effects
  • Dose calculator
  • Research
About
  • About us
  • How we check
  • Manifesto
  • For brands
  • Apply to be listed
  • For clinicians

*These statements have not been evaluated by any medicines agency. Nothing on MyDosage is intended to diagnose, treat, cure or prevent any disease. Research-use-only compounds are not approved for human use. Always talk to a clinician before changing what you take.

© 2026 MyDosage. All rights reserved.
PrivacyTermsFor clinicians
DashboardCheck
Peptides/Exenatide
GLP-1 receptor agonist

Exenatide

Synthetic version of exendin-4 (Gila monster). First-in-class GLP-1 agonist for T2D.

Human RCT · t½ ~2.4 h (IR), ~2 weeks (XR) · 5–10 mcg BID or 2 mg/week

Start with a product

Pick what you have. We'll guide the rest.

Schedule, what to expect, side-effects to watch — built around your exact product.

Scan a productAdd manually
AHuman RCT evidenceHuman RCTGLP-1 receptor agonist

Also: Byetta · Bydureon

Synthetic version of exendin-4 (Gila monster). First-in-class GLP-1 agonist for T2D.

Scientific Consensus Engine

Evidence Intelligence Score™

Heuristic — no indexed evidence yet
6.4/ 10
Overall confidence
Moderate
Outlook
Moderate
Evidence maturity
  1. Preclinical
  2. Pilot human
  3. RCT← current
  4. Multi-RCT
  5. Meta-analysis

Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.

Eight-dimension breakdown
  1. Human evidence
    Weight of RCT and observational data
    8.8
  2. Safety maturity
    Follow-up depth and adverse-event signal
    6.5
  3. Mechanism confidence
    Pathway specificity and clarity
    6.1
  4. Clinical readiness
    Distance to physician-prescribable use
    7.8
  5. Research momentum
    Recency of indexed clinical evidence
    5.0
  6. Study consistency
    Effect direction across cohorts
    4.4
  7. Long-term data
    Follow-up beyond initial trial windows
    5.4
  8. Translational confidence
    Animal → human signal preservation
    7.6
Strongest supported claim

Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.

Weakest / unclear

Effect sizes outside trial populations and durations beyond the studied window remain less characterized.

Major unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Scientific outlook

Outlook: maturing. Expect the consensus to harden as multi-site replications publish.

Reported outcomes · graded
Weight management
Agrade
8.0
Mechanism
GLP-1 receptor agonist; resistant to DPP-4 degradation.
Reported uses
  • Weight managementHuman RCT→
Citations
  • DeFronzo et al., 2005 — Diabetes Care
What we don't know yet
  • —Long-term safety beyond reported study durations.
  • —Effect size in populations under-represented in the cited trials.
  • —Interactions with concomitant medications outside listed contraindications.

We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.

Editorial team
Independent · No affiliate revenue
Reviewed quarterly
Typical dose5–10 mcg BID or 2 mg/week
Half-life~2.4 h (IR), ~2 weeks (XR)
RoutesSubcutaneous
Evidence tierHuman RCT
Safety confidence
Short
Mid
Long-term

No indexed safety data yet — bars reflect editorial tier baseline.

Contraindications
  • — MTC
  • — MEN-2
  • — Severe renal impairment

Suggestive, never prescriptive. Discuss with a clinician.

Brands carrying this peptide

2 brands across three tiers.

Medicine

2 brands

Regulator-approved finished medicines. Prescribed for specific indications, manufactured under GMP, distributed through licensed pharmacies.

  • Byetta
    AstraZeneca
    5 / 10 mcg BID pen
    FDA-approved · EMA
    →
  • Bydureon BCise
    AstraZeneca
    2 mg/week autoinjector
    FDA-approved · EMA
    →